Facing looming Xtandi patent cliff, Astellas pins hopes on more deals while still cutting costs Read more →
Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors Read more →
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions Read more →
